Biological samples bank for childhood cancer treatment effects
Official title: Study of Iatrogenic Effects of Treatment for Childhood Cancer - Constitution of a Biological Samples Bank as Part of a Cohort of Patients (Cohort FCCSS)
Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT02666625 · Data updated 2026-11-12
This project collects saliva and blood from adults who were treated for cancer in childhood to see if genetic differences influence later iatrogenic risks.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 3 sites (Villejuif, Val de Marne and 2 other locations) |
| Status | Recruiting |
| Started | July 23, 2013 |
| Main results expected | December 2036 |
| Study ends | December 2036 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT02666625 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who were treated for a first cancer in childhood and have signed informed consent, with current insurance or social security.
✕Probably not a fit
Individuals who do not consent or who are not adults at enrollment may not benefit directly.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational effort builds a biobank linked to epidemiological studies of late treatment effects in childhood cancer survivors. It aims to identify genetic variants that may modulate risks of non-cancer conditions such as heart, brain, lung, bone, and kidney problems that can arise after childhood cancer treatment. The study collects biological samples and consented clinical data to support future analyses of iatrogenic outcomes. Results could inform prevention strategies for these late effects and improve long-term care for survivors.
Why it matters
Potential benefit: If successful, the biobank could help tailor follow-up and preventive strategies to individual genetic risk profiles in childhood cancer survivors.
How similar studies have gone: Similar biobanking approaches linked to survivorship cohorts have shown promise in identifying genetic factors for late effects, though this specific iatrogenic focus is relatively specialized.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated for a first cancer in childhood * Adult patients * Signed informed consent * Patient insured or enjoying a social security scheme Exclusion Criteria: * Minor patients * Under legal protection measure patients * Refusal of consent
Where it's running
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, France Recruiting -
Centre Léon Bérard
Lyon, France Recruiting -
Institut Curie
Paris, France Recruiting
Study contacts
- Study coordinator: Brice Fresneau, MD
- Email: brice.fresneau@gustaveroussy.fr
- Phone: 0142114622
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse
A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.
-
Cohort for people with chronic myelomonocytic leukemia
This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.
-
ASP3082 for advanced KRAS G12D non-small-cell lung and pancreatic cancers
This study tests whether the experimental drug ASP3082, given once-weekly by IV, helps people with advanced or metastatic non‑small‑cell lung cancer or pancreatic ductal adenocarcinoma that carry a KRAS G12D mutation.
-
Cutting down ultra-processed foods for people at high cancer risk
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
-
Valemetostat for selected solid tumors with SWI/SNF gene alterations
This trial will test whether valemetostat, an EZH1/2 inhibitor, can slow or stop growth in adults whose progressive solid tumors have specific SWI/SNF‑related gene changes.
-
Short-term preoperative elacestrant alone versus elacestrant plus ovarian suppression for premenopausal early-stage ER+/HER2- breast cancer
We will test whether 4 weeks of elacestrant alone or with ovarian suppression lowers the tumor proliferation marker Ki67 in premenopausal women with stage I–II ER+/HER2- breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.